Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders

Basit Öğe Kaydı
dc.contributor.authorSoenmezer, M.
dc.contributor.authorOezmen, B.
dc.contributor.authorCil, A. P.
dc.contributor.authorOezkavukcu, S.
dc.contributor.authorTasci, T.
dc.contributor.authorOlmus, H.
dc.contributor.authorAtabekoglu, C. S.
dc.date.accessioned2020-06-25T17:48:15Z
dc.date.available2020-06-25T17:48:15Z
dc.date.issued2009
dc.departmentKırıkkale Üniversitesi
dc.descriptionOzmen, Batuhan/0000-0002-4504-669X; Atabekoglu, Cem Somer/0000-0003-0264-0709; Ozkavukcu, Sinan/0000-0003-4525-9027
dc.description.abstractThe effect of dehydroepiandrosterone (DHEA) supplementation on cycle outcome was assessed in patients with poor ovarian response. In total, 19 poor responder patients who were scheduled to undergo a second intracytoplasmic sperm injection (ICSI)/embryo transfer cycle were enrolled and first ICSI/embryo transfer cycles were taken as the control group. All subjects were given DHEA supplementation (25 me, t.i.d.) for at least 3 months prior to their second ICSI/embryo transfer cycle. In both cycles a fixed dose of rFSH (300 IU/day) and human menopausal gonadotrophin (HMG) (75 or 150 IU/day) along with a flexible gonadotrophin-releasing hormone (GnRH) antagonist protocol were administered. A favourable decrease was noted in mean day 3 serum oestradiol concentrations after DHEA Supplementation (75.14 +/- 28.93 versus 43.07 +/- 11.77; P < 0.01). Increased number of >17 mm follicles (3 +/- 0.7 versus 1.9 +/- 1.3; P < 0.05), MII oocytes (4 +/- 1.8 versus 2.1 +/- 1.8; P < 0.05), top quality day 2 (2.2 +/- 0.8 versus 1.3 +/- 1.1: P < 0.05) and day 3 embryos (1.9 +/- 0.8 versus 0.7 +/- 0.6; P < 0.05) were achieved in DHEA-supplemented cycles. Cycle cancellation rates were reduced (5.3% versus 42.1%; P < 0.01), and the pregnancy rate per patient and clinical pregnancy rate per embryo transfer (47.4% versus 10.5%; P<0.01 and 44.4% versus 0%; P < 0.01) were improved after DHEA supplementation. DHEA supplementation might enhance ovarian response, reduce cycle cancellation rates and increase embryo quality in poor responders.en_US
dc.identifier.citationclosedAccessen_US
dc.identifier.endpage513en_US
dc.identifier.issn1472-6483
dc.identifier.issn1472-6491
dc.identifier.issue4en_US
dc.identifier.pmid19909591
dc.identifier.scopus2-s2.0-70449127166
dc.identifier.scopusqualityQ1
dc.identifier.startpage508en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12587/4374
dc.identifier.volume19en_US
dc.identifier.wosWOS:000271046800009
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofReproductive Biomedicine Online
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDHEA supplementationen_US
dc.subjectGnRH antagonisten_US
dc.subjectICSIen_US
dc.subjectpoor ovarian responseen_US
dc.titleDehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor respondersen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
Dehydroepiandrosterone supplementation improves ovarian response and cycle outcome in poor responders.pdf
Boyut:
399.83 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin/Full Text
İndir

Koleksiyon

WOS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu